Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 24 of 24 results for vancomycin

  1. Is the application of antiseptics and antibiotics in the operative field before wound closure, clinically and cost effective in reducing surgical site infection rates?

    site infections. However, the evidence for other antibiotics, such as vancomycin, which is widely used worldwide and commonly used in...

  2. Kurin Lock for blood culture collection (HTG715)

    Evidence-based recommendations on Kurin Lock for blood culture collection.

  3. Surgical site infections: prevention and treatment (NG125)

    This guideline covers preventing and treating surgical site infections in adults, young people and children who are having a surgical procedure involving a cut through the skin. It focuses on methods used before, during and after surgery to minimise the risk of infection.

  4. InterDry for intertrigo (MIB192)

    NICE has developed a medtech innovation briefing (MIB) on InterDry for intertrigo .

  5. SepsiTest assay for rapidly identifying bloodstream bacteria and fungi (HTG400)

    Evidence-based recommendations on the SepsiTest assay for rapidly identifying bloodstream bacteria and fungi.

  6. eazyplex SuperBug kits for detecting carbapenemase-producing organisms (MIB94)

    NICE has developed a medtech innovation briefing (MIB) on eazyplex SuperBug kits for detecting carbapenemase-producing organisms .

  7. Boston Keratoprosthesis Type I for corneal blindness (MIB91)

    NICE has developed a medtech innovation briefing (MIB) on Boston Keratoprosthesis Type I for corneal blindness .

  8. Xpert Carba-R to identify people carrying carbapenemase-producing organisms (MIB52)

    NICE has developed a medtech innovation briefing (MIB) on the Xpert Carba-R to identify people carrying carbapenemase-producing organisms

  9. New guidance recommends transplant with good bacteria taken from poo

    Up to 500 people each year could be treated using faecal microbiota transplant for multiple recurrences of Clostridium difficile infections.